A different method of evaluation of the ERSPC trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality

European Urology

Volumn 66, Issue 3, 2014, Pages 401-403

  Zappa, Marco ^a   Puliti, Donella ^a   Hugosson, Jonas ^b   Schröder, Fritz H ^c   Van Leeuwen, Pim J ^c   Kranse, Ries ^c,d   Auvinen, Anssi ^e   Carlsson, Sigrid ^b,f   Kwiatkowski, Maciej ^g,h   Nelen, Vera ⁱ   Borda, Alvaro Paez ^j   Roobol, Monique J ^c   Villers, Arnauld ^k  

^a CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Department of Research and Registration   (Netherlands)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g Department of Urology Kantonsspital Aarau ^*  (Switzerland)

^h Academic Hospital Braunschweig   (Germany)

ⁱ Provinciaal Instituut voor Hygiene   (Belgium)

^j HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^k LILLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Excess mortality; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BLOOD; CAUSE OF DEATH; EARLY DIAGNOSIS; HUMAN; MALE; MORTALITY; PROCEDURES; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL BIAS; STATISTICS;

BIAS (EPIDEMIOLOGY); CAUSE OF DEATH; EARLY DETECTION OF CANCER; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STATISTICS AS TOPIC;

EID: 84905912396     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.12.055     Document Type: Article

References (11)

1. F.H. Schröder, J. Hugosson, and M.J. Roobol et al. Prostate-cancer mortality at 11 years of follow-up N Engl J Med 366 2012 981 990
2. F.H. Schröder, J. Hugosson, and M.J. Roobol et al. Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
3. P. Lenner The excess mortality rate: a useful concept in cancer epidemiology Acta Oncol 29 1990 573 576
4. S.J. Otto, F.H. Schröder, and H.J. de Koning Low all-cause mortality in the volunteer-based Rotterdam section of the European Randomised Study of Screening for Prostate Cancer: self-selection bias? J Med Screen 11 2004 89 92
5. A.G. Bergdahl, G. Aus, H. Lilja, and J. Hugosson Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees Cancer 115 2009 5672 5679
6. P.J. van Leeuwen, R. Kranse, and T. Hakulinen et al. Impacts of a population based prostate cancer screening programme on excess all-mortality rates in men with prostate cancer: a randomized controlled trial J Med Screen 20 2013 33 38
7. R. Kranse, P.J. van Leeuwen, and T. Hakulinen et al. Excess all-cause mortality in the evaluation of a screening trial to account for selective participation J Med Screen 20 2013 39 45
8. K.J. Rothman, and S. Greenland Modern epidemiology ed. 2. 1998 Lippincott-Raven Philadelphia, PA p. 130-1
9. W.C. Black, D.A. Haggstrom, and H.G. Welch All-cause mortality in randomized trials of cancer screening J Natl Cancer Inst 94 2002 167 173
10. H.J. De Koning, J. Blom, and J.W. Merkelbach et al. Determining the cause of death in randomized screening trial(s) for prostate cancer BJU Int 92 Suppl 2 2003 71 78
11. P.J. van Leeuwen, R. Kranse, and T. Hakulinen et al. Disease-specific mortality may underestimate the total effect of prostate cancer screening J Med Screen 17 2010 204 210